SAN DIEGO, July 29 /PRNewswire-FirstCall/ — Anadys
Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that six of six patients
(100%) in the ANA598 200 mg twice daily (bid) arm who were
randomized to stop all treatment at Week 24 in an ongoing Phase II
trial maintained undetectable levels of virus 12 weeks after
stopping treatment, referred to as Sustained
Virological Response 12, or SVR12.
The Company also reported that all available patients from the
ANA598 200 mg arm who were previously reported to have undetectable
levels of virus at Week 24 and continued on pegylated interferon
and ribavirin (current standard of care, or SOC) also maintained
undetectable levels of virus at Week 36. In addition, all
patients from the ANA598 400 mg arm who were previously reported to
have undetectable levels of virus at Week 12 and continued on SOC
maintained undetectable levels of virus at Week 24. ANA598,
Anadys’ direct-acting antiviral or DAA, is being developed to treat
hepatitis C and is in an ongoing Phase II trial in combination with
pegylated interferon and ribavirin.
“The SVR12 data reported today for ANA598 are highly
encouraging,” said Steve Worland,
Ph.D., President and CEO of Anadys. “These data illustrate
the potential for HCV patients to be successfully treated with
shortened courses of treatment, reflecting the continuing benefit
of ANA598 post-therapy. We believe these data, coupled with
the excellent barrier to resistance demonstrated in this trial as
well as the favorable safety and tolerability, confirm ANA598’s
position as one of the most attractive agents in Phase II HCV
development today.”
The si
‘/>”/>
